X-Therma's Latest News
Read the latest news about X-Therma, Cryopreservation and Biopreservation.
X-Therma Showcases Groundbreaking Organ Preservation Technology at Johns Hopkins’ “Hopkins on the Hill” Event
X-Therma Inc., a pioneering biotechnology company revolutionizing organ preservation and regenerative medicine, proudly announces its participation in the prestigious Hopkins on the Hill event, held on June 11, 2025, in Washington, D.C. Hosted by Johns Hopkins University, the biennial event showcased the most impactful federally funded research and innovations across various fields, including artificial intelligence, healthcare technology, and organ transplantation.
X-Therma Welcomes Biotech Veteran Neil Warma to its Board of Directors
X-Therma Inc., a pioneering biotechnology company focused on revolutionizing regenerative medicine through its innovative biopreservation platform, today announced the appointment of Neil Warma, a seasoned healthcare entrepreneur with over 25 years of experience in managing and advising numerous biotechnology and pharmaceutical companies globally, to its Board of Directors.
X-Therma Achieves World’s First Subzero Organ Transports: Multiple 48-Hour Transatlantic Journeys Support First Steps Toward Tackling Organ Waitlist
Surgeons successfully transported pig kidneys between Baltimore and Innsbruck five times using X-Therma’s FDA Breakthrough-designated subzero preservation technology
X-Therma Achieves GMP Commercial Readiness with XT-Thrive®
X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has achieved GMP (Good Manufacturing Practice) commercial readiness with its flagship product, XT-Thrive®.
X-Therma Announces XT-Thrive® Drug Master File (DMF) Accepted by U.S. Food and Drug Administration (FDA)
X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, announces that the Food and Drug Administration (FDA) accepted a Drug Master File (DMF) covering its product, XT-Thrive®.
X-Therma’s $22.4M Series B Sets Stage to Transform Regenerative Medicine and Organ Transplantation
X-Therma Inc., a biotechnology company developing a breakthrough platform for regenerative medicine and organ preservation, has completed an oversubscribed $22.4 million Series B funding round.
Preserve Mammalian Cells At Ultra-Low Temperatures With XT-Thrive®
XT-Thrive® is a DMSO-free, serum-free, protein-free, and chemically defined cryopreservation media for the preservation of mammalian cells at ultra-low temperatures (-70° C to -196° C).
XT-ViVo® & TimeSeal® Multi-Day Preservation of Organs, Tissues And Cells
Learn how XT-ViVo® & TimeSeal® will enable multi-day preservation and remove time from the equation. The global shortage of transplantable organs is considered one of
Advancing Treatment For Type 1 Diabetes With Drs. Camillo Ricordi And Xiaoxi Wei
Dr. Camillo Ricordi may be a familiar name to anyone who has, or has known someone, with type 1 diabetes. As director of the Diabetes
